The Discovery of Dabigatran Etexilate
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation. Thrombin is a key serine protease in the coagulation cascade and numerous efforts have been made to develop safe and effective orally active direct thro...
Main Authors: | Joanne evan Ryn, Ashley M Goss, Norbert eHauel, Wolfgang eWienen, Henning ePriepke, Herbert eNar, Andreas eClemens |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00012/full |
Similar Items
-
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
by: Himabindu Reddy, et al.
Published: (2015-09-01) -
Dabigatran etexilate: a direct thrombin inhibitor
by: M. Dugnani
Published: (2013-05-01) -
Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty
by: Moghtadaee M, et al.
Published: (2012-02-01) -
Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01) -
Acute Myocardial Infarction after Switching from Warfarin to Dabigatran
by: Wael Abuzeid, et al.
Published: (2015-01-01)